Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I)
Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA
(BOTOX®) in adults with chronic migraine.
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA